ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
Dow Jones
39.069,59
0,01%
Euro vs US Dollar
1,08485
0,00%
Bitcoin
69.190,81
-0,11%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Centogene NV (CNTG)

  7. Centogene NV (CNTG) News

CNTG

Centogene NV (CNTG)

Centogene NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CNTG
DatumZeitQuelleÜberschriftSymbolFirma
17/05/202413h20Edgar (US Regulatory)Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).NASDAQ:CNTGCentogene NV
15/05/202423h17GlobeNewswire Inc.CENTOGENE Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:CNTGCentogene NV
15/05/202423h12Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:CNTGCentogene NV
15/05/202423h10GlobeNewswire Inc.CENTOGENE Secures Approx. $20 Million to Strengthen Cash PositionNASDAQ:CNTGCentogene NV
15/05/202423h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
15/05/202422h56Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
14/05/202414h30GlobeNewswire Inc.CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher DiseaseNASDAQ:CNTGCentogene NV
14/05/202414h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
10/05/202412h30GlobeNewswire Inc.CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse PatientsNASDAQ:CNTGCentogene NV
10/05/202412h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
02/04/202422h30GlobeNewswire Inc.CENTOGENE Receives Nasdaq Non-Compliance NoticeNASDAQ:CNTGCentogene NV
19/03/202411h30GlobeNewswire Inc.CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage DisordersNASDAQ:CNTGCentogene NV
29/02/202423h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
29/02/202423h00GlobeNewswire Inc.CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα DeficiencyNASDAQ:CNTGCentogene NV
28/02/202412h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
28/02/202412h30GlobeNewswire Inc.CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a HearingNASDAQ:CNTGCentogene NV
28/02/202412h30GlobeNewswire Inc.CENTOGENE Explores Strategic AlternativesNASDAQ:CNTGCentogene NV
28/02/202412h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
25/01/202412h30GlobeNewswire Inc.CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research CollaborationNASDAQ:CNTGCentogene NV
25/01/202412h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
24/01/202412h30GlobeNewswire Inc.CENTOGENE Receives French Research Tax Credit AccreditationNASDAQ:CNTGCentogene NV
24/01/202412h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
23/01/202412h36Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
23/01/202412h30GlobeNewswire Inc.CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using MultiomicsNASDAQ:CNTGCentogene NV
18/01/202413h02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
18/01/202412h30GlobeNewswire Inc.CENTOGENE Announces Preliminary Full Year 2023 RevenueNASDAQ:CNTGCentogene NV
19/12/202313h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
19/12/202312h30GlobeNewswire Inc.CENTOGENE Announces Voting Results of Extraordinary General MeetingNASDAQ:CNTGCentogene NV
18/12/202312h41Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
13/12/202312h33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CNTGCentogene NV
 Showing the most relevant articles for your search:NASDAQ:CNTG

Kürzlich von Ihnen besucht

LSE
NZGB
Etf S Nzd L Gbp
USOTC
DUAVF
Dassault Aviation Or (PK)
KOSPI
610037
US Treasury Bond 30y ETN...
USOTC
EVTNF
Eviation Aircraft (GM)
COIN
ATMIGBP
USOTC
OPHLY
Ono Pharmaceutical (PK)
USOTC
PRRMF
Premium Income (CE)
USOTC
ALPKF
Alpek SAB DE CV (PK)
LSE
AQTC
USOTC
CUYRF
C Uyemura (PK)
BIT
MIBA
ETF
BIT
S32521
Societe Generale Effekten
COIN
IKONEUR
KRKN
PARAUSD
Parallel Finance
POLO
HARRYUSDT
HarryPotterObamaSonic10Inu
KOSPI
015760
Korea Electric Power
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten